Founder & CEO EMEA @ Rothana | Top 10 LinkedIn Creator in Diabetes | Healthcare Consultant | Leadership Development Specialist | Innovation Strategist | Trainer | Project Manager | Supply Chain Analyst
The Cost of Waiting
In the treatment of serious diabetes-related foot complications, timely assessment matters. Delayed recognition or management particularly when infection, tissue necrosis, or impaired blood flow is present can allow a manageable wound to progress and may increase the risk of hospitalization, surgery, or lower-extremity amputation.
Many of the technologies and clinical approaches needed to improve these outcomes already exist. However, integrating them into routine hospital practice requires more than introducing a medical product. It requires coordinated clinical pathways, trained multidisciplinary teams, reliable referral systems, and sustainable operational infrastructure.
Architecting the Ecosystem
Dr. Ahmed Elawadi is the Chief Executive Officer for EMEA at Rothana, where he leads the expansion of advanced healthcare platforms across multiple regions. His work extends beyond the distribution of medical technologies. He develops the commercial, educational, and operational frameworks needed to support their responsible clinical adoption and help healthcare professionals reach patients more effectively.
From Remote Clinics to Regional Mandates
The foundation of his healthcare career began in an unexpected discipline. He earned a degree in veterinary medicine from Mansoura University before moving into the human healthcare industry. By 2001, he was working with Novartis, supporting cardiovascular products across eleven remote regions. This early exposure to regional differences in healthcare access highlighted the gap that can exist between the availability of medical innovation and its delivery to patients.
He later joined Johnson & Johnson, where he worked with an advanced wound care portfolio. At the time, structured advanced wound management was still developing in many regional hospitals. Instead of focusing only on product promotion, he emphasized clinical education, multidisciplinary engagement, and stakeholder alignment.
He organized the first International Interprofessional Wound Care Course (IIWCC) in Saudi Arabia through a landmark collaboration between the University of Toronto and the Saudi Ministry of Health. The program brought together leading physicians, nurses, and key opinion leaders from across Saudi Arabia, the GCC, and the Levant, creating a regional platform for interprofessional education, evidence-informed practice, and multidisciplinary collaboration in diabetic foot and wound care.
He also managed pricing strategy, tender processes, and educational programs for healthcare professionals. According to his professional record, this approach contributed to triple-digit business growth for three consecutive years.
His career subsequently expanded into broader regional responsibilities. At Acelity and later 3M Health Care, he managed complex tender business, developed distributor networks across the Gulf Cooperation Council and Africa, and led strategic market development. His responsibilities included sales, supply-chain coordination, regulatory requirements, and cross-border commercial operations.
Each role reinforced an important lesson: even a clinically valuable product may fail to achieve meaningful adoption if the surrounding healthcare infrastructure is not prepared to support it.
He further developed his wound care knowledge through the International Interprofessional Wound Care Course at the University of Toronto. The combination of wound care education and extensive commercial experience became a defining feature of his approach: connecting clinical needs with the operational requirements of healthcare delivery.
Building the Infrastructure for Better Outcomes
Today, through Rothana, Dr. Elawadi focuses on scaling technologies intended to improve the assessment, monitoring, and treatment of complex wounds and diabetes-related foot complications. This work requires coordination among regulators, hospital administrators, distributors, and specialized clinicians across healthcare systems with very different resources and structures.
The clinical stakes are significant. Diabetes-related foot infections are among the most frequent diabetes-related complications requiring hospitalization and are a common precipitating event leading to lower-extremity amputation. Outcomes are influenced by several interconnected factors, including infection severity, peripheral arterial disease, neuropathy, delayed presentation, pressure off-loading, metabolic control, and access to multidisciplinary care.
“The biggest adoption barrier in MEA is not necessarily the technology itself; it is workflow integration,” Dr. Elawadi notes. “Many technologies are introduced without being properly embedded into existing clinical routines, referral pathways, hospital systems, professional responsibilities, and reimbursement structures.”
His approach is designed to prevent clinically valuable tools from underperforming because of inadequate implementation. Before a commercial launch, he maps the patient pathway, evaluates distributor capabilities, engages relevant clinical experts, and works to ensure that local healthcare institutions receive the education and operational support needed for sustainable adoption.
“A strong product is important, but the ecosystem around the product ultimately determines whether it succeeds,” he explains. “We focus on understanding the unmet clinical need, identifying the appropriate patient pathways, developing relationships with key opinion leaders, and building confidence in the solution before pursuing broad commercial expansion.”
This structured model allows Rothana to introduce digital and AI-assisted technologies that may support standardized wound measurement, image-based documentation, longitudinal monitoring, risk assessment, and the earlier recognition of concerning changes. These technologies are intended as clinical decision-support tools and should not replace comprehensive assessment or professional judgement.
“My current thesis is that AI will create the greatest near-term value when it augments healthcare professionals rather than attempting to replace clinical judgement,” he states. “In diabetic foot and wound care, practical applications include standardized wound measurement, image-based documentation, risk stratification, and supporting the earlier identification of deterioration.”
Dr. Elawadi applies disciplined operational oversight to these clinical objectives. He reviews opportunity pipelines, new-account activation, training progress, and product-utilization indicators to identify implementation gaps. At the same time, he emphasizes that performance decisions should consider the circumstances facing the people responsible for delivery.
“Empathy in leadership does not mean avoiding difficult decisions,” he says. “It means understanding the human, operational, and commercial realities behind performance before making those decisions.”
Through Rothana, he is working to expand the capabilities of regional wound care systems and improve access to appropriate technologies. He is also pursuing further education in longevity medicine as he prepares for emerging developments in preventive and healthy-ageing healthcare.
The Ultimate Metric
Reducing diabetes-related foot complications will require more than developing better medical devices. It depends on timely assessment, multidisciplinary care, effective referral pathways, appropriate vascular and infection management, patient education, regulatory coordination, and reliable access to evidence-based treatments.
Dr. Ahmed Elawadi has spent more than two decades developing the commercial and clinical environments needed to support healthcare innovation across diverse markets. His work is directed toward ensuring that medical technologies are introduced responsibly, integrated effectively, and made available where they can contribute to better patient care.
The ultimate measure of success is not simply the number of products introduced or hospitals supplied. It is whether the resulting healthcare system helps clinicians intervene earlier, improve healing, preserve mobility, and reduce avoidable complications including preventable amputations.
Dr. Ahmed Elawadi is the Chief Executive Officer EMEA of Rothana and is based in Dubai, United Arab Emirates. He develops commercial and clinical ecosystems supporting advanced wound care, medical technology, and emerging longevity solutions across international markets. To connect with Dr. Elawadi or learn more about his work, visit https://www.rothana.com/ or his LinkedIn profile. Dr Ahmed Elawadi , IIWCC | LinkedIn
